Journal Article10.1126/science.abn1755
COVID-19 vaccination: The road ahead
192
TL;DR: A diverse array of successful, first-generation SARS-CoV-2 vaccines have played a huge role in efforts to bring the COVID-19 pandemic under control, even though inequitable distribution still leaves many vulnerable.
read more
Abstract: A diverse array of successful, first-generation SARS-CoV-2 vaccines have played a huge role in efforts to bring the COVID-19 pandemic under control, even though inequitable distribution still leaves many vulnerable. Additional challenges loom for the next phase. These include optimizing the immunological rationale for boosting—how often and with what—and the best approaches for building a future-proofed, durable immune repertoire to protect against oncoming viral variants, including in children. The landscape of vaccine producers and technologies is likely to become even more heterogeneous. There is a need now for appraisal of future approaches: While some favor frequent boosting with the first-generation, ancestral spike vaccines, others propose frequent readjustment using current variant sequences, polyvalent vaccines, or pan-coronavirus strategies. Description
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Characterization of COVID-19 vaccine clinical trial discussions on the social question-and-answer site Quora
Qing Xu,Tiana McMann,Jiawei Li,Christine Wenzel,Tim K. Mackey +4 more
TL;DR: This study found active user discussions related to COVID-19 vaccine clinical trials on Quora, including those specific to minority health topics and those posted by a smaller group of self-identified racial and ethnic minority online users.
2
Mucosal response of inactivated and recombinant COVID‐19 vaccines in Congolese individuals
Freisnel H. Mouzinga,Constanze Heinzel,Abel Lissom,Andrea Kreidenweiss,Armel Landry Batchi-Bouyou,Jacques Dollon Mbama Ntabi,Jean Claude Djontu,Etienne Ngumbi,P. G. Kremsner,Rolf Fendel,Francine Ntoumi +10 more
TL;DR: Little information is available about the induction of mucosal immunity by inactivated and recombinant coronavirus disease 2019 (COVID‐19) vaccines, and this study aims to investigate this topic.
2
Neutralizing antibody levels and epidemiological information of patients with breakthrough COVID-19 infection in Toyama, Japan
TL;DR: In this paper , the authors analyzed the possession status of neutralizing antibodies in patients with Breakthrough Infection after CoV-19 vaccination using SARS-CoV-2 pseudotyped viruses.
Vacunación del adulto en atención primaria: durante y después de pandemia
Mariana Blanco-Betancur,Jose F. Díez-Concha,Maria F. García-Trochez,Liliana P. Zambrano-Pabón,Viviana M. Rivera-Eraso,Jorge A. Sánchez-Duque +5 more
TL;DR: In this paper , a revisión narrativa is sintetizar las recomendaciones actuales de vacunación en la población adulta of Colombia and América Latina with un enfoque en atención primaria.
2
Appropriate Human Serum Albumin Fluid Therapy and the Alleviation of COVID-19 Vulnerabilities: An Explanation of the HSA Lymphatic Nutrient Pump
TL;DR: In this article , the authors proposed a lymphatic nutrient pump (HSALNP) to ensure continual pumping of nutrients from the liver and ensure that nutrients are appropriately distributed to organs.
References
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
David S. Khoury,Deborah Cromer,Arnold Reynaldi,Timothy E. Schlub,Timothy E. Schlub,Adam K. Wheatley,Jennifer A Juno,Kanta Subbarao,Stephen J. Kent,Stephen J. Kent,Stephen J. Kent,James A. Triccas,Miles P. Davenport +12 more
TL;DR: It is shown that neutralization level is highly predictive of immune protection, and an evidence-based model of SARS-CoV-2 immune protection that will assist in developing vaccine strategies to control the future trajectory of the pandemic is provided.
SARS-CoV-2 variants, spike mutations and immune escape.
William T. Harvey,Alessandro M Carabelli,Ben Jackson,Ravindra K. Gupta,E. Thomson,E. Thomson,Ewan M. Harrison,Ewan M. Harrison,Catherine Ludden,Richard Reeve,Andrew Rambaut,Sharon J. Peacock,David Robertson +12 more
TL;DR: A review of the literature on mutations of the SARS-CoV-2 spike protein, the primary antigen, focusing on their impacts on antigenicity and contextualizing them in the protein structure is presented in this article.
Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses
Shuo Su,Gary Wong,Weifeng Shi,Jun Liu,Jun Liu,Alexander Lai,Jiyong Zhou,Wenjun Liu,Yuhai Bi,George F. Gao +9 more
TL;DR: This review aims to compare and contrast the different HCoVs with regard to epidemiology and pathogenesis, in addition to the virus evolution and recombination events which have, on occasion, resulted in outbreaks amongst humans.
2.9K
Adaptive immunity to SARS-CoV-2 and COVID-19.
TL;DR: In this article, a picture has begun to emerge that reveals that CD4+ T cells, CD8+ Tcells, and neutralizing antibodies all contribute to control SARS-CoV-2 in both non-hospitalized and hospitalized cases of COVID-19.
1.7K
DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
Jingyou Yu,Lisa H. Tostanoski,Lauren Peter,Noe B. Mercado,Katherine McMahan,Shant H. Mahrokhian,Joseph P. Nkolola,Jinyan Liu,Zhenfeng Li,Abishek Chandrashekar,David R. Martinez,Carolin Loos,Caroline Atyeo,Stephanie Fischinger,John S. Burke,Matthew D. Slein,Yuezhou Chen,Adam Zuiani,Felipe J.N. Lelis,Meghan Travers,Shaghayegh Habibi,Laurent Pessaint,Alex Van Ry,Kelvin Blade,Renita Brown,Anthony Cook,Brad Finneyfrock,Alan Dodson,Elyse Teow,Jason Velasco,Roland Zahn,Frank Wegmann,Esther A. Bondzie,Gabriel Dagotto,Makda S. Gebre,Xuan He,Catherine Jacob-Dolan,Marinela Kirilova,Nicole Kordana,Zijin Lin,Lori F. Maxfield,Felix Nampanya,Ramya Nityanandam,John D. Ventura,Huahua Wan,Yongfei Cai,Bing Chen,Aaron G. Schmidt,Duane R. Wesemann,Ralph S. Baric,Galit Alter,Hanne Andersen,Mark G. Lewis,Dan H. Barouch,Dan H. Barouch +54 more
TL;DR: Analysis of the vaccine candidates in rhesus macaques showed that animals developed protective humoral and cellular immune responses when challenged with the SARS-CoV-2 virus, suggesting an immune correlate of protection.
1.1K